At 10.7% CAGR, Asia Pacific Fill Finish Manufacturing Market is Projected to be Worth US$ 4,202.36 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific fill finish manufacturing market was valued at US$ 1,867.35 million in 2022 and is expected to reach US$ 4,202.36 million by 2030, registering a CAGR of 10.7% from 2022 to 2030. Elevating demand for biologics and growing adoption of prefilled syringes for parenteral administration are among the critical factors attributed to the Asia Pacific fill finish manufacturing market expansion.             

Biologics constitute a majority of the top-selling drugs, and they represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies ~30 years ago, the overall biologics market has grown at an annual rate of more than 12%. Further, over 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are the key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduces the requirement of capital investments, provides access to larger production capacities, decreases the time-to-market of products, and lowers risks associated with the commercialization of products.

Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Fill finish manufacturing services are currently provided by approximately 180 companies for a variety of biologics. They are located in over 350 fill finish factories for these contract manufacturing companies across various geographic regions.

On the contrary, growing competition in biopharmaceutical contract manufacturing industry hurdles the growth of Asia Pacific fill finish manufacturing market. 

Based on product, the Asia Pacific fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held 57.8% share of Asia Pacific fill finish manufacturing market in 2022, amassing US$ 1,079.52 million. It is projected to garner US$ 2,500.90 million by 2030 to expand at 11.1% CAGR during 2022–2030. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.

In terms of modality, the Asia Pacific fill finish manufacturing market is categorized into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held 32.4% share of Asia Pacific fill finish manufacturing market in 2022, amassing US$ 605.49 million. It is projected to garner US$ 1,412.39 million by 2030 to expand at 11.2% CAGR during 2022–2030.

By end user, the Asia Pacific fill finish manufacturing market is segmented into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held 51.0% share of Asia Pacific fill finish manufacturing market in 2022, amassing US$ 951.69 million. It is projected to garner US$ 2,186.87 million by 2030 to expand at 11.0% CAGR during 2022–2030.

Based on country, the Asia Pacific fill finish manufacturing market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 32.7% share of Asia Pacific fill finish manufacturing market in 2022. It was assessed at US$ 609.69 million in 2022 and is likely to hit US$ 1,426.22 million by 2030, exhibiting a CAGR of 11.2% during 2022–2030.            

Key players operating in the Asia Pacific fill finish manufacturing market are Becton Dickinson and Co, Gerresheimer AG, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Asia Pacific NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc, among others.

• In January 2022, West Pharmaceutical Services Inc announced an exclusive supply and technology agreement with Corning Inc. The new collaboration includes a multimillion-dollar investment to expand Corning's Valor Glass technology to enable advanced injectable drug packaging and delivery systems for the pharmaceutical industry with the goal of advancing patient safety and expanding access to life-saving treatments. This partnership and investment enable the development and industry-leading solutions that enhance patient safety, increase quality and reliability in highly regulated markets, and ensure greater capacity for life-saving drugs. West is a great partner. The combination of Corning's Valor Glass, along with West's NovaPure components, is a win-win for customers and patients all over the world.
• In February 2023, Gerresheimer and Corning announced joint venture to meet growing demand for Velocity Vials. The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity Vial technology platform, helping set a new standard for the industry. Pharmaceutical companies will benefit from improved filling line performance with increased throughput and yield, lowering their total cost of ownership.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com